FDA's May 28 approval of Natesto, the first nasally delivered testosterone gel for hypogonadism, came just in time for Canada's Trimel Pharmaceuticals, which had just $18 million left on hand at the beginning of the year.
A team of biomedical engineers, venture capitalists and device businesspeople are launching a new incubator for med tech startups in Silicon Valley.
Researchers at Boston's Brighman and Women's Hospital used a 3-D bioprinting method to create functional synthetic blood vessels that could someday be used develop transplanted tissues and test drugs outside the body.
Vaccine developer Advaxis is teaming up with CRO inVentiv Health to advance a stable of oncology candidates that work by mounting an immune system attack on cancer tissue.
Results are in from a showdown between chronic lymphocytic leukemia drugs Imbruvica, from Johnson & Johnson's Janssen unit, and GlaxoSmithKline's Arzerra. And as it turns out, it wasn't much of a contest.
Now that the Pfizer takeover AstraZeneca fought to avoid is on the rocks--at least for the time being--the pressure's on the British drugmaker to deliver strong growth on its own. And while much of the attention is focused on its pipeline, leading cancer drug Zoladex may be able to chip in, too, with new data suggesting it could help prevent infertility in some breast cancer patients receiving chemo.
On Thursday, John Carroll and Dr. David Porter, one of the top investigators on the CAR-T team at the University of Pennsylvania, discussed how this program promises to be a game changer in cancer treatment in the first of a three-part Twitter chat around this year's ASCO conference. Here is a wrapup of the conversation.
After failing to buy Illumina in 2012 and deciding to close its 454 Life Sciences sequencing unit last year, Roche has been looking for technologies to strengthen its diagnostic business.
Glaxo announced at ASCO on Sunday that in a Phase III study, Tykerb and Herceptin failed to improve disease-free survival in HER2-positive early breast cancer patients over Herceptin on its own.
Samsung Electronics' digital health strategy relies on a wrist-bound wearable device with cloud-based data-sharing software that enables third-party development of biosensors and medical mobile apps, the company announced May 28 in San Francisco.